Evidence map›Paper›PMID 40656616›Full record

Trial reportWorld journal of gastroenterology2025

Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease.

Antonio Liguori, Maria E Ainora, Luca Di Gialleonardo, Nicholas Viceconti, Lucrezia Petrucci, Giorgio Esposto, Maria C Giustiniani, Irene Mignini, Raffaele Borriello, Linda Galasso and 8 more

Abstract readClinical Trial
In one paragraph

Trial report in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Antonio LiguoriUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Maria E AinoraCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Luca Di GialleonardoCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Nicholas VicecontiUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Lucrezia PetrucciUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Giorgio EspostoCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Maria C GiustinianiDipartimento di Scienze Della Salute Della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Irene MigniniCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Raffaele BorrielloCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Linda GalassoCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Mattia ParatoreCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Matteo GarcovichCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Laura RiccardiCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Maurizio PompiliUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Antonio GriecoUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Antonio GasbarriniCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Luca MieleUnità di Medicina Interna e Trapianto di Fegato, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy.
Maria A ZoccoCEMAD, Centro Malattie Apparato Digerente, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy. mariaassunta.zocco@unicatt.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn metabolic dysfunction-associated steatotic liver disease (MASLD) the identification of patients at high risk of evolution to metabolic dysfunction-associated steatohepatitis (MASH) is challenging.

aimTo investigate the performance of different ultrasound (US)-based techniques for the non-invasive assessment of liver fibrosis, steatosis, and inflammation in these patients.

methodsWe collected data from consecutive patients who underwent liver biopsy for suspected MASLD between January 2019 and December 2021. Two-dimensional shear-wave elastography, sound speed plane-wave US, attenuation plane-wave US, viscosity plane-wave US (Vi.PLUS) using Aixplorer MACH 30 system, and transient elastography and controlled attenuation parameter from FibroScan were measured before biopsy.

resultsA total of 120 participants were enrolled. Both transient elastography and two-dimensional shear-wave elastography showed good performance for the diagnosis of advanced fibrosis [area under the receiver operating characteristic curve (AUROC) = 0.93 and 0.90, respectively]. The diagnostic performance of Vi.PLUS for the presence of both ballooning grade ≥ 1 and lobular inflammation ≥ 1 was good with an AUROC of 0.72. A score based on Vi.PLUS, aspartate aminotransferase, and sound speed plane-wave US [viscosity-aspartate aminotransferase-speed of sound MASH ultrasound score (VAS-MASH-US score)] had a good accuracy for the diagnosis of MASH (AUROC = 0.75). VAS-MASH-US score > 0.6 showed a good sensitivity for MASH diagnosis (79.0%). According to decision curve analysis, the application of the VAS-MASH-US score would lead to a more accurate selection of patients who are candidates to undergo liver biopsy and would reduce the need for invasive procedures for patients at low risk of MASH.

conclusionMultiparametric US allows the non-invasive assessment of steatosis, inflammation, and fibrosis in patients with MASLD. Liver viscosity improved the capability of non-invasively identifying patients with MASH.

Indexed as

Elasticity Imaging TechniquesFatty LiverLiver CirrhosisAdultAgedBiopsyFemaleHumansInflammationLiverMaleMiddle AgedROC CurveSeverity of Illness IndexUltrasonographyLiver fibrosisLiver inflammationLiver viscosityMetabolic dysfunction-associated steatotic liver diseaseMultiparametric ultrasound

Identifiers

PMID40656616
PMCPMC12243859

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.